Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

hibitor, PCI-27483, is currently being evaluated in a multicenter Phase I/II randomized study in patients with locally advanced or metastatic pancreatic cancer. As planned, we have completed the Phase I portion of this Phase I/II trial and have successfully advanced to Phase II. In the Phase II portion of this study each pancreatic cancer patient will receive a maximum of 12 weeks of treatment with gemcitabine alone or gemcitabine plus PCI-27483. As of to date we have dosed 11 pancreatic cancer patients and the study continues enrolling in the randomized Phase II segment of the trial. We anticipate completing enrollment of 46 patients in the second half of 2011.
  • Histone deacetylase (HDAC) Inhibitor, PCI-24781, is the company's orally-bioavailable HDAC Inhibitor that disrupts DNA repair and contributes to tumor cell death. In 3 Phase I clinical trials, conducted in patients with hematologic or solid tumors, clinical response or control of tumor growth has been observed following single-agent therapy with our HDAC Inhibitor. Pharmacyclics' HDAC Inhibitor has demonstrated a good safety profile in approximately 90 patients treated so far; the main dose-limiting toxicity was a rapidly reversible thrombocytopenia, which we believe is related to the pharmacologic mechanism of action. The magnitude of thrombocytopenia can be attenuated by modification of the treatment schedule. The Phase II portion of our ongoing trial is continuing in patients with follicular and mantle cell lymphoma.  Results are anticipated in the second half of 2011. To date we have enrolled 7 follicular and 3 mantle cell patients; so far in this study 1 patient had a partial response and 4 patients have reported stable disease after 2 cycles.
  • The HDAC Inhibitor PCI-24781 has also shown synergy in preclinical testing with several approved cancer therapeutics. A Phase I/II trial in sarcoma patients is ongoing and is co-sponsored by prominent investigators at Massachuse
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... non-statutory stock options to purchase an aggregate of 67,700 ... The awards were made pursuant to the NASDAQ inducement ... employment compensation. The inducement grants were approved ... are being made as an inducement material to each ...
    (Date:8/1/2014)... 2014  With monumental health reform coming into effect, ... language. Clinical efficacy is no longer the sole driver ... like PCORI are directing roughly $1 billion a year ... and environments, the federal healthcare ecosystem is changing, and ... outcomes and managed markets to the right people in ...
    (Date:8/1/2014)... LAVAL, Quebec and NEW YORK ... Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management, L.P. ... by Allergan, Inc. (NYSE: AGN ) in ... Pershing Square regarding the tender offer rules.  ... an attempt to interfere with shareholders, efforts to call ...
    Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
    ... , BOSTON, Nov. 17 ... and information management solutions, today announced that it will showcase ... (IDNs) at the 2009 Radiological Society of North America (RSNA) ... IL. AMICAS will be in the North Hall in booth ...
    ... HistoRx today announced that the Company,s proprietary AQUA technology, ... was noted in a recent National Comprehensive Cancer ... testing in breast cancer as one of the "... promising ... PgR in breast cancer tissue." Experts from the country,s ...
    Cached Medicine Technology:AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 2AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 3AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force 2
    (Date:8/1/2014)... August 02, 2014 The successful development ... stamping business of Guangdong FODAY Automobile Co.,LTD. As early ... company had already organized an excellent team to develop ... of detailed, in-depth technical plans. The company’s vice president ... in the direct involvement of the specific arrangement and ...
    (Date:8/1/2014)... one of the most famous dress suppliers in the world, ... online. At the moment, all the brand new items ... to the company’s senior spokesman, the special offer will last ... is limited. Those who are thinking of buying cheap bridesmaid ... All its products are delicately made by top designers. ...
    (Date:8/1/2014)... Cannabis use among young people has spiked, with ... used marijuana at least once and 17 percent admitting to ... Drugs, Say ‘Yes to Life,’ volunteers from the Church of ... with factual information about drugs, to help reverse this alarming ... to Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 ...
    (Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
    (Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
    Breaking Medicine News(10 mins):Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2
    ... over 100 NFL Legends Announced, TAMPA, Fla., ... (GGAF) today announced an unprecedented humanitarian,initiative to assist ... U.S. Military Special Operations personnel and their families,through ... partnership today and unveiled a Gridiron Greats Super ...
    ... Mickey,s accidental death (October 18th) Hunter has been,changing ... Outreach,Foundation as National Spokesperson., CHICAGO, Nov. 12 ... Epilepsy Outreach Foundation (AEOF),joins with Hunter Tylo of ... nationwide,campaign to raise awareness of Epilepsy and educate ...
    ... accuracy of their annual formulations for human influenza vaccines ... the time, especially for seniors. Perhaps in part because ... upcoming influenza strains, approximately 36,000 people die each year ... the case of hurricanes, early warning of the location ...
    ... Nov. 12 As the exclusive official,breaking news service ... PR Newswire is featuring profiles of the exhibiting,organizations. The ... Company : Linemaster Switch ... Web URL : ...
    ... to ... reduces errors and hospital costs, DAYTONA BEACH, ... medication error reduction and hospital pharmacy I.V.,room automation, recently ... IntelliFill i.v.(TM), by the Alegent Health System. The,largest not-for-profit, ...
    ... Increased use of computers to create predictive models ... organised by the European Science Foundation (ESF), which ... the field. Human disease research produces an enormous ... animal models, high throughput genetic screening of human ...
    Cached Medicine News:Health News:Warriors Unite: Mike Ditka & the Gridiron Greats Form Partnership to Assist Retired NFL Players & U.S. Military Special Operations Personnel 2Health News:Warriors Unite: Mike Ditka & the Gridiron Greats Form Partnership to Assist Retired NFL Players & U.S. Military Special Operations Personnel 3Health News:November: National Epilepsy Awareness Month Actress Hunter Tylo Turns Tragic Loss Into Hope 2Health News:A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks 2Health News:A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks 3Health News:A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks 4Health News:Linemaster Switch Corporation Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:Computers make sense of experiments on human disease 2Health News:Computers make sense of experiments on human disease 3
    ... Proven tension-free sling technology ... porcine acellular collagen matrix sling, ... tissue-to-tissue contact between sling and ... urethral or vaginal abrasion or ...
    ... Delivers the advanced performance ... exceptional strength, versatility, and durability ... implant that augments the effectiveness ... pelvic floor reconstruction. Comprised of ...
    ... system is a state-of-the-art, comprehensive cardiac ... programs, modalities, and parameters are highly ... multiple applications including cardiac and pulmonary ... clinics. Its open architecture delivers flexibility ...
    NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
    Medicine Products: